Enzo Biochem, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Segment reporting (Tables)

Segment reporting (Tables)

12 Months Ended

Jul. 31, 2012

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:


	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated

Revenues:
Clinical laboratory services	$	59,403			—			—			—		$	59,403
Product revenues		—		$	37,722			—			—			37,722
Royalty and license fee income		—			5,958			—			—			5,958

Total revenues		59,403			43,680			—			—			103,083


Operating expenses:
Cost of clinical laboratory services		36,305			—			—			—			36,305
Cost of product revenues		—			19,668			—			—			19,668
Research and development		299			4,308		$	1,686			—			6,293
Selling, general and administrative		20,856			18,305			—		$	8,767			47,928
Provision for uncollectible accounts receivable		4,987			117			—			—			5,104
Legal		262			536			—			2,926			3,724
Impairment charges		—			24,540			—			—			24,540

Total operating expenses		62,709			67,474			1,686			11,693			143,562


Operating loss		(3,306	)		(23,794	)		(1,686	)		(11,693	)		(40,479	)

Other income (expense)
Interest		(5	)		23			—			3			21
Other		28			27			—			22			77
Foreign exchange loss		—			(540	)		—			—			(540	)


Loss before income taxes	$	(3,283	)	$	(24,284	)	$	(1,686	)	$	(11,668	)	$	(40,921	)


Depreciation and amortization included above	$	1,092		$	3,217		$	43		$	125		$	4,477


Share-based compensation included in above:
Cost of clinical laboratory services	$	10						—			—		$	10
Research and development		—		$	4			—			—			4
Selling, general and administrative		49			59			—		$	597			705

Total	$	59		$	63			—		$	597		$	719


Capital expenditures	$	921		$	443			—		$	—		$	1,364


	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated

Revenues:
Clinical laboratory services	$	52,762						—			—		$	52,762
Product revenues		—		$	41,830			—			—			41,830
Royalty and license fee income		—			7,437			—			—			7,437

Total revenues		52,762			49,267			—			—			102,029

Operating expenses:
Cost of clinical laboratory services		31,682			—			—			—			31,682
Cost of product revenues		—			22,137			—			—			22,137
Research and development		—			5,784		$	2,022			—			7,806
Selling, general and administrative		18,426			17,855			—		$	8,910			45,191
Provision for uncollectible accounts receivable		4,415			16			—			—			4,431
Legal		387			726			—			2,597			3,710

Total operating expenses		54,910			46,518			2,022			11,507			114,957


Operating (loss) income		(2,148	)		2,749			(2,022	)		(11,507	)		(12,928	)

Other income (expense)
Interest		(5)			2			—			14			11
Other		30			(3	)		—			18			45
Foreign exchange gain		—			49			—			—			49

(Loss) income before income taxes	$	(2,123	)	$	2,797		$	(2,022	)	$	(11,475	)	$	(12,823	)


Depreciation and amortization included above	$	1,012		$	3,282		$	47		$	128		$	4,469


Share-based compensation included in above:
Cost of clinical laboratory services	$	10			—		$	—			—		$	10
Research and development		—		$	14			—			—			14
Selling, general and administrative and legal		61			84			—		$	880			1,025

Total		71			98		$	—		$	880		$	1,049


Capital expenditures	$	834		$	389		$	—		$	—		$	1,223


	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated

Revenues:
Clinical laboratory services	$	44,178			—			—			—			44,178
Product revenues		—		$	43,111			—			—		$	43,111
Royalty and license fee income		—			9,793			—			—			9,793

Total revenues		44,178			52,904			—			—			97,082

Operating expenses:
Cost of clinical laboratory services		29,570						—			—			29,570
Cost of product revenues		—			22,547			—			—			22,547
Research and development		—			7,202		$	2,502			—			9,704
Selling, general and administrative		18,503			19,800			—		$	10,092			48,395
Provision for uncollectible accounts receivable		3,432			48			—			—			3,480
Legal		222			145			—			1,379			1,746
Litigation settlement		—			—			—			3,698			3,698

Total operating expenses		51,727			49,742			2,502			15,169			119,140


Operating (loss) income		(7,549	)		3,162			(2,502	)		(15,169	)		(22,058	)

Other income (expense)
Interest		—			(5	)		—			24			19
Other		46			(8	)		—			6			44
Foreign exchange loss		—			(266	)		—			—			(266	)

(Loss) income before income taxes	$	(7,503	)	$	2,883		$	(2,502	)	$	(15,139	)	$	(22,261	)


Depreciation and amortization included above	$	982		$	3,110		$	52		$	125		$	4,269


Share-based compensation included in above:
Cost of clinical laboratory services	$	12					$	—			—		$	12
Research and development		—		$	14			—			—			14
Selling, general and administrative and legal		78			114			—		$	952			1,144

Total	$	90		$	128		$	—		$	952		$	1,170


Capital expenditures	$	1,728		$	1,450		$	11		$	62		$	3,251

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

Geographic financial information is as follows:


Net sales to unaffiliated customers:	2012		2011		2010

United States	$	87,776	$	85,691	$	82,873
Switzerland		6,802		8,508		7,037
United Kingdom		2,728		2,825		2,507
Other international countries		5,777		5,005		4,665

Total	$	103,083	$	102,029	$	97,082


Long-lived assets at July 31,	2012		2011		2010

United States	$	25,081	$	44,028	$	45,439
Switzerland		2,223		8,958		7,063
United Kingdom		618		2,857		2,944
Other international countries		426		1,850		1,723

Total	$	28,348	$	57,693	$	57,169

Schedule Of Segment Revenue By Geographical [Table Text Block]

The following is a summary of the Life Sciences segment revenues attributable to customers located in the United States and foreign countries:


	2012		2011		2010

United States	$	28,372	$	32,928	$	38,695
Foreign countries		15,308		16,339		14,209

	$	43,680	$	49,267	$	52,904

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References + Details

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details